回顾性分析疏风解毒胶囊联合西医治疗普通型新型冠状病毒肺炎患者的临床疗效

陈灵; 柳芳; 吴金虎; 宋红艳; 夏敬胜; 盛碧; 陈永刚

doi:10.13422/j.cnki.syfjx.20201628

您当前的位置：

首页 >

文章列表页 >

回顾性分析疏风解毒胶囊联合西医治疗普通型新型冠状病毒肺炎患者的临床疗效

特异性PCR的应用专题 | 更新时间：2023-07-12

- 回顾性分析疏风解毒胶囊联合西医治疗普通型新型冠状病毒肺炎患者的临床疗效
- Clinical Efficacy of Shufeng Jiedu Capsule Combined with Western Medicine in Treatment of Common COVID-19 Patients by Retrospective Analysis
- 中国实验方剂学杂志 2020年26卷第16期页码：14-20
- 作者机构：
  
  1.武汉市第三医院（武汉大学附属同仁医院），武汉 430060
  2.中日友好医院，北京 100029
- 作者简介：
  
  陈灵，硕士，主管中药师，从事临床中药学研究，E-mail：57776228@qq.com
  盛碧，硕士，主管药师，从事临床药学研究，E-mail：512511203@qq.com
- 基金信息：
  
  中医药防治新型冠状病毒感染的肺炎应急研究专项(2020ZYLCYJ03-10)
- DOI：10.13422/j.cnki.syfjx.20201628
  中图分类号： R22;R242;R2-031;R287
- 网络出版日期：2020-06-11，
  
  纸质出版日期：2020-08-20
- 稿件说明：
移动端阅览
陈灵,柳芳,吴金虎等.回顾性分析疏风解毒胶囊联合西医治疗普通型新型冠状病毒肺炎患者的临床疗效[J].中国实验方剂学杂志,2020,26(16):14-20.

CHEN Ling,LIU Fang,WU Jin-hu,et al.Clinical Efficacy of Shufeng Jiedu Capsule Combined with Western Medicine in Treatment of Common COVID-19 Patients by Retrospective Analysis[J].Chinese Journal of Experimental Traditional Medical Formulae,2020,26(16):14-20.
陈灵,柳芳,吴金虎等.回顾性分析疏风解毒胶囊联合西医治疗普通型新型冠状病毒肺炎患者的临床疗效[J].中国实验方剂学杂志,2020,26(16):14-20. DOI： 10.13422/j.cnki.syfjx.20201628.

CHEN Ling,LIU Fang,WU Jin-hu,et al.Clinical Efficacy of Shufeng Jiedu Capsule Combined with Western Medicine in Treatment of Common COVID-19 Patients by Retrospective Analysis[J].Chinese Journal of Experimental Traditional Medical Formulae,2020,26(16):14-20. DOI： 10.13422/j.cnki.syfjx.20201628.

摘要

目的

分析联合应用疏风解毒胶囊治疗普通型新型冠状病毒肺炎（coronavirus disease-2019，COVID-19）患者的临床疗效。

方法

采取倾向性评分匹配研究法，选择2020年1月27日至2020年3月5日在武汉市第三医院就诊的符合普通型COVID-19患者的临床资料，符合纳排标准的疏风解毒胶囊联合常规治疗患者34例为治疗组，倾向性配对1∶1，常规治疗患者34例为对照组。比较两组主要症状（发热、咳嗽、咯痰、乏力）的消失率、消失天数、有效率，其他症状消失率，治疗7 d前后的实验室指标差异，肺部计算机断层扫描（CT）有效率，转重率及总住院时间等。

结果

两组基线资料比较，差异无统计学意义，具有可比性。治疗7 d，治疗组咳嗽、咯痰、乏力、胸闷、喘气的消失率高于对照组（

0.05）；治疗组主要症状平均消失天数明显少于对照组（

0.05）；治疗组主要症状治疗有效率明显高于对照组（

0.05）；治疗组有8.8%（3/34）的患者转重型，对照组有26.5%（9/34）的患者转重型，差异无统计学意义；治疗7 d，与本组治疗前比较，治疗组淋巴细胞明显上升（

0.05），C反应蛋白，降钙素原，D-二聚体水平明显下降（

0.05）；对照组淋巴细胞明显上升（

0.05），C反应蛋白明显下降（

0.05）；治疗组肺部CT改善率91.2%（31/34），明显高于对照组70.6%（24/34，

0.05）；两组患者治疗后均痊愈出院，治疗组平均住院时间（15.53±2.63）d，对照组平均住院时间（16.35±4.98）d，差异无统计学意义；治疗组无不良事件，对照组出现了3例不良事件。

结论

联合应用疏风解毒胶囊能明显改善普通型COVID-19患者的咳嗽、咳痰、乏力、胸闷、喘气的临床症状，提高主要症状有效率，调控相关外周血炎症指标的表达，促进肺部炎症吸收，提高治愈率，提示疏风解毒胶囊可以有效地应用于普通型COVID-19患者治疗中。

Abstract

Objective

To analyze the clinical efficacy of Shufeng Jiedu Capsule (SFJD capsule) combined with western medicine in the treatment of common coronavirus disease-2019 (COVID-19).

Method

By the usage propensity score matching

the clinical data of COVID-19 patients with common COVID-19 admitted to Wuhan third hospital from January 27

2020 (solstice) to March 5

2020

were screened out. Thirty-four patients with SFJD capsule combined with conventional therapy according to the inclusion and exclusion criteria were enrolled in treatment group

and 34 patients treated with conventional therapy were enrolled in control group. The disappearance rate of main symptoms (fever

cough

expectoration and fatigue)

days of syndrome disappearance

effective rate and disappearance rate of other symptoms

laboratory indexes before treatment and after 7 days′ treatment

effective rate of computed tomography (CT) of the lungs

rate of COVID-19 severe transformation and hospitalization time between the two groups were compared.

Result

The baseline data between the two groups showed no statistically significant difference

and was comparable. After 7 days of treatment

the symptom disappearance rate of cough

sputum

fatigue

chest tightness and panting in treatment group was significantly higher than that in control group (

0.05). The average days of disappearance of main symptoms in treatment group was significantly less than that in control group (

0.05). The effective rate of main symptom was significantly higher than control group (

0.05). In treatment group

8.8%（3/34） of the patients were transferred to severe disease

while 26.5%（9/34） of the patients in control group were transferred to severe disease

with statistically significant differences. After treatment for 7 days

lymphocytes in treatment group significantly increased (

0.05)

C-reactive protein significantly decreased (

0.05)

procalcitonin level significantly decreased (

0.05)

and D-dimer level significantly decreased (

0.05)

while lymphocytes in control group significantly increased (

0.05)

and c-reactive protein significantly decreased (

0.05). The improvement rate of pulmonary CT in treatment group was 91.2%（31/34）

which was significantly higher than 70.6%（24/34） in control group (

0.05). After treatment

both groups were cured and discharged

the average length of stay in treatment group was (15.53±2.63) d

which was (16.35±4.98) d in control group，with no statistically significant difference. No adverse events occurred in treatment group

but 3 cases occurred in control group.

Conclusion

SFJD capsule combined with western medicine can significantly improve the clinical symptoms of normal COVID-19 patients

such as cough

sputum

fatigue

chest distress and shortness of breath

alleviate the main symptoms effectively

regulate the expressions of relevant peripheral inflammation

promote the absorption of lung inflammation

and improve the cure rate

which indicates that SFJD capsule can be effectively in the treatment of patients with common COVID-19.

关键词

Keywords

references

国家卫生健康委，国家中医药管理局 . 新型冠状病毒肺炎诊疗方案（试行第七版） [EB/OL]. http://www.nhc.gov.cn/yzygj/s7653p/202003/46c9294a7dfe4cef80dc7f5912eb1989.shtml.2020-03-04/2020-03-28 http://www.nhc.gov.cn/yzygj/s7653p/202003/46c9294a7dfe4cef80dc7f5912eb1989.shtml.2020-03-04/2020-03-28 .

世界卫生组织．关于2019新型冠状病毒疫情的《国际卫生条例(2005)》突发事件委员会第二次会议的声明 [EB /OL]． https://www.Who.int /zh /news-room/ ， 2020-01-31 / 2020-02-17 ．

GUAN W J ， NI Z Y ， HU Y ， et al ． Clinical characteristics of coronavirus disease 2019 in China [J]． N Engl J Med , 2020 , 382 ( 18 ): 1708 - 1720 .

夏文广 , 安长青 , 郑婵娟 , 等．中西医结合治疗新型冠状病毒肺炎34例临床研究 [J]. 中医杂志 , 2020 , 61 ( 5 ): 375 - 382 .

李素云 , 李高阳 , 张华茹 , 等．祛肺毒一号方治疗新型冠状病毒肺炎重型/危重型患者临床疗效分析 [J]. 中国实验方剂学杂志 , 2020 , 26 ( 11 ): 13 - 20 .

王饶琼 , 杨思进 , 谢春光 , 等．清肺排毒汤治疗新型冠状病毒肺炎的临床疗效观察 [J]. 中药药理与临床 , 2020 , 36 ( 1 ): 13 - 18 .

鲍岩岩 , 高英杰 , 时宇静 , 等 . 疏风解毒胶囊广谱抗病毒功效研究 [J]. 新中医 , 2019 , 51 ( 12 ): 5 - 8 .

曹利芳 , 唐超 , 夏静 , 等 . 疏风解毒胶囊治疗AECOPD合并肺部感染的疗效观察 [J]. 中国中医急症， 2019 ， 28 ( 9 ): 1636 - 1638 .

刘静 , 马莉 , 陆洁 , 等 . 疏风解毒胶囊解热作用机制研究 [J]. 中草药， 2016 ， 47 ( 12 ): 2040 - 2043 .

马莉 , 黄妍 , 侯衍豹 , 等 . 疏风解毒胶囊对大鼠肺炎模型的抗炎机制研究 [J]. 中草药 , 2018 , 49 ( 19 ): 4591 - 4595 .

马莉 , 黄妍 , 侯衍豹 , 等 . 疏风解毒胶囊免疫调节作用机制研究 [J]. 药物评价研究 , 2019 , 42 ( 9 ): 1763 - 1768 .

李宏军 . 新型冠状病毒肺炎影像学辅助诊断指南 [J]. 中国医学影像技术， 2020 ， doi： 10.13929/j.issn.1003-3289.2020.03.001 http://dx.doi.org/10.13929/j.issn.1003-3289.2020.03.001 .

王艳芳 , 陈建普 , 王翔 . 新型冠状病毒肺炎无症状感染者的CT影像分析 [J]. 武汉大学学报：医学版 , 2020 , 41 ( 3 ): 353 - 356 .

马亦林 . 冠状病毒的特性及其致病性研究进展 [J]. 中华临床感染病杂志 , 2018 , 11 ( 4 ): 305 - 315 .

HAN W Z , QUAN B , GUO Y , et al . The course of clinical diagnosis and treatment of a case infected with coronavirus disease 2019 [J]. J Med Virol , 2020 , 92 ( 5 ): 461 - 463 .

LU H Z . Drug treatment options for the 2019-new coronavirus (2019-nCoV) [J]. Biosci Trends , 2020 , 14 ( 1 ): 69 - 71 .

LIU X Y , ZHANG H B , XU J , et al . Identification of absorbed components and their metabolites in rat plasma after oral administration of Shufeng Jiedu capsule using ultra-performance liquid chromatography/quadrupole time-of-flight mass spectrometry [J]. Rapid Commun Mass Spectrom , 2019 , 33 ( 19 ): 1494 - 1501 .

TAO Z G , GAO J Y , ZHANG G L , et al . Shufeng Jiedu capsule protect against acute lung injury by suppressing the MAPK/NF- κ B pathway [J]. BioSci Trends , 2014 , 8 ( 1 ): 45 - 51 .

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

回顾性分析甘露消毒汤联合西医治疗普通型新型冠状病毒肺炎患者的临床疗效

单中心儿童肾病综合征临床诊疗及中药用药规律分析

紫朱软膏联合清筋术治疗非缺血型糖尿病足溃疡的临床疗效及对血清NLRP3、IL-1β、IL-18水平的影响

基于以“味”统方、苦辛平逆法的葶鹿益心饮治疗射血分数保留型心力衰竭合并糖尿病的临床疗效

芪附益心方治疗慢性心力衰竭心气虚证患者的临床疗效